Physician profile
Samuel E Inkumsah
NPI 1629242490
$1,760.95
in general payments reported to CMS, 2019-2025
30 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.68 · 2021: $133 · 2022: $534 · 2023: $379 · 2024: $342 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.25 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $119.75 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $112.98 | 2023-2025 | Nuzyra |
| Pfizer INC. | $96.54 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.97 | 2022 | |
| Amgen INC. | $63.61 | 2023-2024 | Krystexxa, Evenity, Prolia |
| Smith+Nephew, INC. | $56.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.08 | 2021-2025 | Airsupra |
| Shield Therapeutics INC | $47.34 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $45.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.57 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $42.77 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $40.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.97 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.64 | 2022 | |
| Cranial Technologies, INC | $31.33 | 2023 | Doc Band |
| Horizon Therapeutics Plc | $28.83 | 2023 | Krystexxa |
| Abbott Laboratories | $23.35 | 2024 | Freestyle Libre 3 |
| Tolmar, INC. | $20.46 | 2025 | Jatenzo |
| Tris Pharma INC | $18.40 | 2024 | Dyanavel Xr |
| Seqirus USA INC | $17.94 | 2025 | Fluad, Flucelvax |
| Impel Pharmaceuticals INC. | $17.26 | 2022 | |
| Edwards Lifesciences Corporation | $16.35 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.00 | 2022 | |
| Ardelyx, INC. | $14.98 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $14.70 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.49 | 2022 | |
| Esperion Therapeutics, INC. | $14.19 | 2022 | |
| Currax Pharmaceuticals LLC | $13.93 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Inkumsah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.